Results 61 to 70 of about 22,199 (155)

Can the Development of Orphan Drugs Include Wider Patient Engagement? A Citizens' Jury to Explore a Promissory Notion. [PDF]

Health Expect
Frost J, Widening Engagement Patient Advisory Group, Mandizha J, van den Dungen C, Asare L, Pope C.   +5 more
europepmc   +1 more source

Federal 340B Program Payment Scheme for Drugs Designated As Orphan Products: Congressional Clarification Needed to Close the Government-Industry Revolving Door [PDF]

Journal of Clinical Oncology, 2016
Yang, Y. Tony, Chen, Brian, Bennett, Charles L.   +2 more
openaire   +2 more sources

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes. [PDF]

Front Med Technol
Haon B, Hartmann M, Akodad S, Stevens H, Rochaix L.   +4 more
europepmc   +1 more source

Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access. [PDF]

Clinicoecon Outcomes Res
Rawson NSB.
europepmc   +1 more source

Assessing rare disease understanding: a novel disease readiness level framework. [PDF]

Orphanet J Rare Dis
Kitahara K, Kano S.
europepmc   +1 more source

Navigating market access after conditional reimbursement: a communication roadmap for disinvesting orphan drugs. [PDF]

Int J Technol Assess Health Care
Abdallah K, Blonda A, Godman B, Huys I, Claes K, Denier Y, Simoens S.   +6 more
europepmc   +1 more source

The imperative for national legislation on rare diseases in China: A policy review and call to action. [PDF]

Intractable Rare Dis Res
Li Y, Liu Z, Huang R, Liu Y.
europepmc   +1 more source

Addressing challenges along the 'access cascade' for new TB regimens. [PDF]

IJTLD Open
Servello J, de Colombani P, Dall'Olio L, Gargioni G, Raviglione MCB.   +4 more
europepmc   +1 more source

PHP6 QUANTITATIVE ANALYSIS OF THE INFLUENCE OF DISEASE AND PRODUCT CHARACTERISTICS ON ORPHAN DRUG PRICES IN EUROPE

Value in Health, 2010
Aballea, S, Toumi, M, Vataire, AL, Millier, A, Lamure, M   +4 more
openaire   +1 more source

Concurrent nanotherapeutics and regulatory updates for the management of amyotrophic lateral sclerosis: a focused review for orphan drug (Tofersen). [PDF]

Orphanet J Rare Dis
Kumar A, Shukla S, Rai A, Pathak P, Narayan KP.   +4 more
europepmc   +1 more source